uniQure Announces Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease ~ Enrollment of second dose cohort expected to begin in 3Q 2021 ~ ~ Company announces plans to initiate a second clinical study of AMT-130 in Europe in the second half of 2021 ~ LEXINGTON, Mass....

uniQure Provides Update on Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B ~ Third patient treated in Phase IIb study ~ ~ Topline data expected to be available before the end of 2018 ~ LEXINGTON, Mass and AMSTERDAM, the Netherlands, Sept. 24, 2018 (GLOBE NEWSWIRE) --...